About
Radiopharmaceuticals based on linking single domain antibody fragments with radioisotopes to treat cancer
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalRadiopharmaceuticalsAntibody
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
22
By Phase
PHASE1/PHASE2: 1PHASE1: 1
By Status
TERMINATED: 1COMPLETED: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Today
Hover over trial bars to see details
Recent Trials
NCT04467515Lead Sponsor
A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer
PHASE1/PHASE2Terminated
13 participants
Started: Sep 14, 2021 · Completed: Dec 11, 2023
NCT02683083Lead Sponsor
Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients
PHASE1Completed
9 participants
Started: Oct 31, 2016 · Completed: Feb 5, 2018
Locations (1)
Headquarters
Brussels, Belgium
Map
Loading map...